Company / SG&A Expense
ImmunityBio, Inc. SG&A Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$168.8M
FY2024
5-year range
$46.5M / $168.8M
FY2020-FY2024
Trend
+30.2%
vs FY2023
Sector context
#83 of 213
Health Care
What the data says
At $169M, ImmunityBio, Inc.'s sg&a expense ranks #131 of 213 in the Health Care sector. SG&A Expense has increased for 3 consecutive years, from $46M in FY2021 to $169M in FY2024.
Based on SEC 10-K filings.
$169M in FY2024 with a 5-year CAGR of +29.4%.
Increased from $103M to $169M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +53.7%
- 5-Year CAGR
- +29.4%
- 10-Year CAGR
- -
Sector benchmark
#131 of 213 in Health CareTop 61% of 213This company $168.8M Sector average $722.3M
▼
-76.6% below sector average
Key checks
Key Insights
- ImmunityBio, Inc.'s sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +29.4%, indicating consistent growth.
- In FY2024, sg&a expense increased 30.2% year-over-year.
- Ranks #83 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -7.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $168.8M | +30.2% |
| FY2023 | $129.6M | +26.2% |
| FY2022 | $102.7M | +121.1% |
| FY2021 | $46.5M | -34.9% |
| FY2020 | $71.3M | +53.5% |
| FY2019 | $46.5M | -51.3% |
| FY2018 | $95.4M | -58.1% |
| FY2017 | $227.7M | +4827.0% |
| FY2016 | $4.6M | -98.0% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026